Precision BioSciences offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific t...

Read More

DTIL Performance At-A-Glance

RISK EFFICIENCY

-0.95

Precision BioSciences Inc's risk efficiency is -0.95, which is poor. By comparison, the S&P500 is 0.44.

Increasing quickly  over the past 4 weeks.

DSCORE

7.80%

Precision BioSciences Inc's dScore is 7.8% , which is more volatile than the S&P500 (1.74%).

GROWTH

-70.59%

Precision BioSciences Inc has shrunk by -70.59% over the past year.  By comparison, the S&P500 has lost NaN%.